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difficulty in achieving hemostasis. Coagulation studies revealed a decreasing number of platelets and fibrinogen concentration at 30 days after admission. Furthermore, compared witht he normal range, FDP and D-dimer concentrations were elevated (Table 1) . Based on his markedly increased plasma concentrations of thrombin -antithrombin complex (TAT) and plasminplasmin inhibitor complex (PIC), he was diagnosed as having fibrinolysis dominant DIC, 3 which is characterized by the activation of both coagulation and fibrinolysis. The usual level of PIC is above 4 g/ml. Computed tomography showed an AAA measuring 50 mm in diameter and existence of wall thrombus under the bifurcation of the renal artery (Fig 1) .
There was no indication for surgery for the AAA because the patient was bedridden. To control the hemorrhagic diathesis by consumption coagulopathy, various treatments were tried, including danaparoid only, UFH, nafamostat mesilate (FUT) and combined therapy of danaparoid and tranexamic acid (Table 2) . Finally, based on the patient's condition, we chose a regimen of danaparoid 1,250 U/day (total 2,500 U/day) intravenously and tranexamic acid 0.5 g/day (total 1.5 g/day) by oral administration. The combined therapy control his hemorrhagic diathesis and prolonged his survival for more than 2 years. ONTACHI Y et al.
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Treatments (Table 2 ) Danaparoid intravenously at an initial dose of 1,250 U/day (up to 2,500 U/day based on the clinical course). The platelet count and fibrinogen concentration increased slightly, but hemorrhagic diathesis did not improve.
UFH subcutaneously at an initial dose of 5,000 U/day, despite which the hemorrhagic diathesis was aggravated.
FUT continuous infusion at 0.1 mg · kg -1 · h -1 , with dramatic improvement of hemostasis and the clinical symptoms. However, because of the adverse effects of FUT, namely hyperkalemia and renal insufficiency, it could not be continued.
Combined Therapy of Danaparoid and Tranexamic Acid (Fig 2) Danaparoid was administered intravenously at 2,500 U/day (1,250 U ×2), with 1.5 g/day (0.5 g ×3) tranexamic acid administered orally. The D-dimer concentration decreased and fibrinogen concentration increased. Furthermore, the bleeding tendency improved. Tranexamic acid had to be stopped temporarily during sepsis, because of organ dysfunction. However, danaparoid therapy only caused worsening of the hemorrhagic diathesis.
Discussion
The cornerstone of the management of DIC is the treatment of the underlying disorder. 1 However, the general condition of the current patient rendered him inoperable and furthermore, his hemorrhagic tendency progressed to include nasal bleeding and ecchymosis, and thus continuous treatment for DIC was required. In patients with DIC, local activation of coagulation results in the systemic depletion of coagulation factors and platelets, 1 and the basic principal for treating DIC is anticoagulation therapy, such as heparin. 7, 8, 11, 12 Cummins et al reported that long-term treatment with LMWH could provide good symptomatic control of chronic DIC associated with AAA, 5 and as far as we could ascertain, there is not a great difference between LMWH and UFH. However, subcutaneous injection was ruled out because of the large purpura at the site of injection and so we needed to use a drug that could be administered as a bolus injection.
Danaparoid is a mixture of sulfated glycosaminoglycans, and its pharmacological properties differ from those of UFH or LMWH. 13 Although UFH can inhibit thrombin (IIa) and activated factor X (Xa) equally, danaparoid has a high anti-Xa/anti-IIa ratio. The overall anti-Xa/anti-IIa ratio is about 20 compared with a ratio of 1 for UFH and of between 2 and 4 for LMWH. 14 As danaparoid inhibits platelet adherence much less than UFH, its effect on bleeding is less marked, 14 but it has a longer half-life of 20 h. 10 In Western countries, danaparoid sodium is used for venous thromboembolism and heparin-induced thrombocytopenia. 9 Clinical hemorrhagic diathesis accompanying aortic aneurysms was first reported in 1971 15 and is now well recognized. 5, 7, 16 The activation of coagulation in such cases may be caused by tissue factor from subendothelial elements. In a previous study, we reported that the degree to which the fibrinolytic system is activated varies according to the underlying disease responsible for DIC and we have named the condition involving a markedly enhanced fibrinolytic system as "fibrinolysis dominant DIC". 3 The fibrinolysis dominant DIC is characterized by the activation of both coagulation and fibrinolysis and according to our proposition, DIC associated with aortic aneurysm is fibrinolysis dominant DIC. The representative disease of fibrinolysis dominant DIC is acute promyelocytic leukemia (APL). 17 One feature of APL is that it is associated with severe coagulopathy, which may lead to life-threatening bleeding, and it has been attributed to DIC and fibrinolysis. 18 The clinical hemorrhagic diathesis accompanying aortic aneurysms is considered to be the same condition as APL because of the remarkable increase in PIC and decrease in 2 plasmin inhibitor ( 2 PI).
Tranexamic acid has been proposed as the hemostatic agent in many clinical conditions characterized by excessive bleeding, but its use in patients with DIC is generally not recommended. 1 We previously demonstrated that tranexamic acid increased organ dysfunction in a tissue factor induced rat DIC model. 19 On the other hand, there are case reports of the efficacy of tranexamic acid against the hemorrhage caused by DIC. 20, 21 At the present time, it is not evident whether the use of tranexamic acid for DIC is effective or safe. In the present patient, from the viewpoint of the characteristics of DIC, danaparoid was useful for inhibiting the activation of coagulation and preventing thrombotic complications, whereas tranexamic acid was useful for controlling hemorrhage. As shown in the Fig 2, the TAT concentration was constantly elevated, which suggests that the use of anticoagulant was justified in this case. On the other hand, the changes in PIC correlated with the bleeding symptoms. Measuring the concentration of PIC makes it possible to monitor the use of an antifibrinolytic. At the onset of sepsis in March, the transient decrease in the concentration of PIC shows the inhibitory conditions of fibrinolysis, which was confirmed by the changes in the FDP/D-dimer ratio. Although the concentration of 2 PI similarly shows the degree of activation of fibrinolysis, with regard to the present case, it did not decrease compared with the PIC or FDP/D-dimer ratio. One reason for this is that 2 PI is acute phase reactant. It may be more useful to measure PIC, FDP/D-dimer ratio and 2 PI for the monitoring of a fibrinolysis dominant DIC case, such as the present one.
As for the dosages, taking into account his creatine clearance, we selected a relatively lower dose of tranexamic acid than that of the past report (3-6 g/day) and although IV administration may be needed for rapid improvement, we selected oral administration for long-term control of DIC.
In summary, not all patients with AAA can be surgically treated, and cases with DIC may require anticoagulation therapy. Based on the long half-life of danaparoid, combined therapy with tranexamic acid enables control of this hemorrhagic complication. Such therapy may be beneficial for chronic DIC, in particular for fibrinolysis dominant DIC, and may allow control of the bleeding without restricting the movement of patients by a continuous drip.
